EGFRvIII-specific CAR-T cells produced by piggyBac transposon exhibit efficient growth suppression against hepatocellular carcinoma.
In conclusion, EGFRvIII CAR-T cells demonstrated specific antitumor effect against SMMC7721 in vitro and in vivo, providing basis for immunotherapy of HCC in future clinical use.
PMID: 32624697 [PubMed - in process]
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
More News: Biomedical Science | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Genetics | Hematology | Hepatocellular Carcinoma | Immunotherapy | Liver | Liver Cancer | Urology & Nephrology